BioRestorative Therapies, Inc. BRTX
Nasdaq · XNAS · stock · Services-Misc Health & Allied Services, NEC
Chart by TradingView
3/9
Piotroski F — financial health
-162.4
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $359,700 | -$14.2M | $335,856 | -$10.9M | $356,744 |
| 2024 | $401,000 | -$9.0M | $372,928 | -$8.3M | $8.5M |
| 2023 | $145,800 | -$10.4M | $145,800 | -$6.6M | $10.0M |
| 2022 | $119,800 | -$18.5M | — | -$6.2M | $10.3M |
| 2021 | $46,000 | -$44.3M | — | -$3.4M | $21.6M |
| 2020 | $77,000 | -$11.3M | — | — | -$1.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Silva Francisco | VP of Research and Development | 2025-10-06 | Grant | 11,719 | $1.60 |
| ALSTODT LANCE | President, CEO, COB | 2025-10-06 | Grant | 15,625 | $1.60 |
| Broadrick Dale | 10% owner | 2024-10-28 | Sell | 1,112 | $1.58 |
| Silva Francisco | VP of Research and Development | 2024-04-09 | Buy | 6,600 | $1.25 |
| Silva Francisco | VP of Research and Development | 2024-04-08 | Buy | 476 | $1.13 |
| Silva Francisco | VP of Research and Development | 2024-04-08 | Buy | 1,232 | $1.17 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -162.4 (distress)
- Working capital / assets -0.144
- Retained earnings / assets -41.651
- EBIT / assets -3.835
- Equity / liabilities 0.096
Source: SEC EDGAR filings · CIK 0001505497 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.